4.03 USD
↘ 0.01 (0.25%)AT CLOSE (11:59 AM EDT)
Mannkind Corporation
MNKDNASDAQ • USD
4.02
↘ 0.01 (0.35%)
POST MARKET (AS OF 05:19 PM EDT)
Post Market
AS OF 05:19 PM EDT
4.02
↘ 0.01 (0.35%)
Market: OPEN
Mannkind Corporation (MNKD) trades at $4.08 per share. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (40.4%) and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 17, 2026.
Open?$4.00
High?$4.15
Low?$3.95
Prev. Close?$4.04
Volume?3.5M
Avg. Volume?4.9M
VWAP?$4.06
Rel. Volume?0.71x
Bid / Ask
Bid?$3.50 × 100
Ask?$4.63 × 100
Spread?$1.13
Midpoint?$4.06
Valuation & Ratios
Market Cap?1.2B
Shares Out?309.0M
Float?277.4M
Float %?89.8%
P/E Ratio?N/A
P/B Ratio?-21.09
EPS?-$0.08
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Employees
592
Market Cap
1.2B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2004-07-28
Address
1 CASPER STREET
DANBURY, CT 06810
Phone: 818-661-5000
DANBURY, CT 06810
Phone: 818-661-5000
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?35
Short Sent.?70
Piotroski F-Score?3/9Weak
Altman Z-Score?-4.35Distress
Confidence?55%Low
Short InterestElevated
Short % of Float?9.44%Elevated
Short Interest?26.2M
Days to Cover?4.4
Free Float277.4M
Avg Daily Volume5.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.87Adequate
Quick Ratio?1.50Adequate
Cash Ratio?0.39Low
Debt/Equity?-8.22Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score60/100
P/E?N/A▾
P/B?-21.09CHEAP▾
S&P97
P/S?3.46FAIR▾
Peers100
S&P44
P/FCF?94.9PRICEY▾
Peers100
S&P3
EV/EBITDA?47.6HIGH▾
Peers100
S&P3
EV/Sales?4.66FAIR▾
Peers100
S&P39
Returns & Efficiency
ROE?40.4%STRONG▾
Peers50
S&P88
ROA?-3.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$13.2M
Enterprise Value?$1.7B
Fundamentals ratios updated end of day